AbbVie (ABBV) EPS (Basic) (2012 - 2026)

AbbVie (ABBV) has reported EPS (Basic) for 15 consecutive years, with $2.04 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 284.05% year-over-year to $2.04 in Q2 2026; TTM through Jun 2026 was $3.57, a 67.39% increase from a year earlier, with the FY2025 full-year figure at $2.39, down 1.24% from the prior year.
• EPS (Basic) was $2.04 for Q2 2026 at AbbVie, up from $0.39 in the prior quarter.
• Over five years, EPS (Basic) peaked at $2.54 in Q1 2022 and troughed at -$0.05 in Q1 2023.
• A 5-year average of $0.92 and a median of $0.78 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) plunged 102.79% in 2024 and jumped 7991.3% in 2025, its largest moves.
• Over 5 years, EPS (Basic) stood at $1.4 in 2022, then plunged by 66.61% to $0.47 in 2023, then sank by 102.79% to -$0.01 in 2024, then jumped by 7991.3% to $1.03 in 2025, then surged by 99.23% to $2.04 in 2026.
• The last three EPS (Basic) figures came in at $2.04 (Q2 2026), $0.39 (Q1 2026), and $1.03 (Q4 2025), per Business Quant data.